ArticleACS medicinal chemistry letters2012
Prodrugs of a CXC Chemokine-12 (CXCL12) Neutraligand Prevent Inflammatory Reactions in an Asthma Model in Vivo.
Article in ACS medicinal chemistry letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- Design, Synthesis and Biological Evaluation of Prodrugs of 666-15 as Inhibitors of CREB-Mediated Gene Transcription.ACS medicinal chemistry letters · 2022Article
- An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation.Acta pharmaceutica Sinica. B · 2021Article
- A Selective Neutraligand for CXCL12/SDF-1α With Beneficial Regulatory Functions in MRL/Lpr Lupus Prone Mice.Frontiers in pharmacology · 2021Article
- Identification of Interleukin-8-Reducing Lead Compounds Based on SAR Studies on Dihydrochalcone-Related Compounds in Human Gingival Fibroblasts (HGF-1 cells) In Vitro.Molecules (Basel, Switzerland) · 2020Article
- Pharmacological tools to mobilise mesenchymal stromal cells into the blood promote bone formation after surgery.NPJ Regenerative medicine · 2020Article
- Two distinct CXCR4 antagonists mobilize progenitor cells in mice by different mechanisms.Blood advances · 2017Article
- Chalcone Derivatives: Promising Starting Points for Drug Design.Molecules (Basel, Switzerland) · 2017Review
- The Prodrug Approach: A Successful Tool for Improving Drug Solubility.Molecules (Basel, Switzerland) · 2015Review
- A strategy to discover decoy chemokine ligands with an anti-inflammatory activity.Scientific reports · 2015Article
- An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in mice.The Journal of biological chemistry · 2013Article
- Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction.Current topics in medicinal chemistry · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chalcone 4 (compound 1) is a small molecule that neutralizes the CXC chemokine CXCL12 and prevents it from acting on the CXCR4 and CXCR7 receptors. To overcome its poor solubility in aqueous buffers, we designed highly soluble analogues of compound 1, phosphate, l-seryl, and sulfate, all inactive by themselves on CXCL12 but when cleaved in vivo into 1, highly active locally at a low dose in a mouse airway hypereosinophilia model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.